Investment in Unconsolidated Entities (Tables)
|
12 Months Ended |
Dec. 31, 2019 |
Neuro Partners LLC and CGK [Member] |
|
Schedule of Equity Method Investments [Line Items] |
|
Equity Method Investment Summarized Financial Information |
The following tables present the aggregation of summarized financial information of NeuroPartners LLC and CGK:
Neuro Partners LLC and CGK Combined Condensed Income Statement Information | | | | | | Year Ended December 31, | | | | 2019 | | | 2018 | | | | | | | | | Patient revenue | | $ | 1,020,000 | | | $ | 1,141,000 | | | | | | | | | | | Net income | | $ | 303,000 | | | $ | 590,000 | | | | | | | | | | | USNC’s equity in income of Neuro Partners LLC and CGK | | $ | 92,000 | | | $ | 181,000 | |
Neuro Partners LLC and CGK Combined Condensed Balance Sheet Information | | | | | | December 31, | | | | 2019 | | | 2018 | | | | | | | | | Current assets | | $ | 163,000 | | | $ | 304,000 | | | | | | | | | | | Noncurrent assets | | | 807,000 | | | | 1,064,000 | | | | | | | | | | | Total assets | | $ | 970,000 | | | $ | 1,368,000 | | | | | | | | | | | Current liabilities | | $ | 380,000 | | | $ | 399,000 | | | | | | | | | | | Noncurrent liabilities | | | 593,000 | | | | 924,000 | | | | | | | | | | | (Deficit) equity | | | (3,000 | ) | | | 45,000 | | | | | | | | | | | Total liabilities and (deficit) equity | | $ | 970,000 | | | $ | 1,368,000 | |
|
FOP [Member] |
|
Schedule of Equity Method Investments [Line Items] |
|
Equity Method Investment Summarized Financial Information |
The following tables present the summarized financial information of FOP:
FOP Condensed Income Statement Information | | | | | | | | | | Year Ended | | | | 2019 | | | 2018 | | | | | | | | | Patient revenue | | $ | 1,922,000 | | | $ | 2,953,000 | | | | | | | | | | | Rental Income | | $ | 543,000 | | | $ | 1,252,000 | | | | | | | | | | | Net loss | | $ | (1,377,000 | ) | | $ | (1,918,000 | ) | | | | | | | | | | USNC’s equity in loss of FOP | | $ | (334,000 | ) | | $ | (465,000 | ) |
FOP Condensed Balance Sheet Information | | | | | | December 31, | | | | | 2019 | | | | 2018 | | | | | | | | | | | Current assets | | $ | 165,000 | | | $ | 401,000 | | | | | | | | | | | Noncurrent assets | | | 1,202,000 | | | | 16,570,000 | | | | | | | | | | | Total assets | | $ | 1,367,000 | | | $ | 16,971,000 | | | | | | | | | | | Current liabilities | | $ | 4,003,000 | | | $ | 3,974,000 | | | | | | | | | | | Noncurrent liabilities | | | 1,091,000 | | | | 15,360,000 | | | | | | | | | | | Equity | | | (3,727,000 | ) | | | (2,363,000 | ) | | | | | | | | | | Total liabilities and equity | | $ | 1,367,000 | | | $ | 16,971,000 | |
|
Boca Oncology Partners RE, LLC ("BOPRE") [Member] |
|
Schedule of Equity Method Investments [Line Items] |
|
Equity Method Investment Summarized Financial Information |
The following tables present the summarized financial information of BOPRE:
BOPRE Condensed Income Statement Information | | | | | | Years Ended December 31, | | | | | | | | 2019 | | | 2018 | | | | | | | | | Rental Income | | $ | - | | | $ | - | | | | | | | | | | | Net income (loss) | | $ | 46,000 | | | $ | (4,000 | ) | | | | | | | | | | USNC’s equity in income (loss) in BOPRE | | $ | 11,000 | | | $ | (1,000 | ) |
BOPRE Condensed Balance Sheet Information | | | |
| | December 31, | | | | 2019 | | | 2018 | | | | | | | | | Current assets | | $ | 64,000 | | | $ | 18,000 | | | | | | | | | | | Noncurrent assets | | | 935,000 | | | | 935,000 | | | | | | | | | | | Total assets | | $ | 999,000 | | | $ | 953,000 | | | | | | | | | | | Current liabilities | | $ | - | | | $ | - | | | | | | | | | | | Noncurrent liabilities | | | - | | | | - | | | | | | | | | | | Equity | | | 999,000 | | | | 953,000 | | | | | | | | | | | Total liabilities and equity | | $ | 999,000 | | | $ | 953,000 | |
|
Medical Oncology Partners LLC [Member] |
|
Schedule of Equity Method Investments [Line Items] |
|
Equity Method Investment Summarized Financial Information |
The following table presents the summarized financial information of MOP:
MOP Condensed Consolidated Income Statement Information | | | | | Years Ended December 31, | | | | |
| 2019 | | 2018 | | | | | | | Patient revenue | | $ | 2,669,000 | | | $ | 2,257,000 | | | | | | | | | | | Net loss | | $ | (435,000 | ) | | $ | (282,000 | ) | | | | | | | | | | USNC’s equity in loss in MOP | | $ | (156,000 | ) | | $ | (101,000 | ) |
MOP Condensed Consolidated Balance Sheet Information | | | | | | December 31, | |
| | 2019 | | | 2018 | | | | | | | | | Current assets | | $ | 247,000 | | | $ | 41,000 | | | | | | | | | | | Noncurrent assets | | | 807,000 | | | | 159,000 | | | | | | | | | | | Total assets | | $ | 1,054,000 | | | $ | 200,000 | | | | | | | | | | | Current liabilities | | $ | 1,907,000 | | | $ | 1,002,000 | | | | | | | | | | | Noncurrent liabilities | | | 427,000 | | | | 33,000 | | | | | | | | | | | Deficit | | | (1,280,000 | ) | | | (835,000 | ) | | | | | | | | | | Total liabilities and deficit | | $ | 1,054,000 | | | $ | 200,000 | |
|
CB Oncology Partners LLC [Member] |
|
Schedule of Equity Method Investments [Line Items] |
|
Equity Method Investment Summarized Financial Information |
The following table presents the summarized financial information of CBOP:
CBOP Condensed Income Statement Information | | | | | | Years Ended December 31, | | | | | | | | | | | 2019 | | | 2018 | | | | | | | | | Patient revenue | | $ | 1,637,000 | | | $ | 956,000 | | | | | | | | | | | Net loss | | $ | (418,000 | ) | | $ | (1,230,000 | ) | | | | | | | | | | USNC’s equity in loss of CBOP | | $ | (101,000 | ) | | $ | (298,000 | ) |
CBOP Condensed Balance Sheet Information | | | | | | December 31, | | | | 2019 | | | 2018 | | | | | | | | | Current assets | | $ | 380,000 | | | $ | 140,000 | | | | | | | | | | | Noncurrent assets | | | 4,869,000 | | | | - | | | | | | | | | | | Total assets | | $ | 5,249,000 | | | $ | 140,000 | | | | | | | | | | | Current liabilities | | $ | 3,026,000 | | | $ | 1,618,000 | | | | | | | | | | | Noncurrent liabilities | | | 4,019,000 | | | | - | | | | | | | | | | | Deficit | | | (1,796,000 | ) | | | (1,478,000 | ) | | | | | | | | | | Total liabilities and deficit | | $ | 5,249,000 | | | $ | 140,000 | |
|